RGC Regencell Bioscience Holdings Ltd Annual reports only
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1829667
Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-226.5%
TTM EPS YoY-229.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-128.5%
ROA-114.2%
ROIC (approx.)-1,159.2%
Asset turnover—
Leverage & solvency
Liabilities / assets9.4%
Debt / equity0.00x
Current ratio10.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-39.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $1.30M | $948,289 | $1.07M | $1.58M | $2.51M |
| SG&A expense | $10.42M | $2.81M | $3.55M | $4.43M | $5.08M |
| Operating income | -$11.72M | -$3.77M | -$4.74M | -$6.27M | -$7.62M |
| Pretax income | -$11.70M | -$3.58M | -$4.36M | -$6.06M | -$7.59M |
| Net income | -$11.70M | -$3.58M | -$4.30M | -$5.87M | -$7.45M |
| EBITDA | -$11.64M | -$3.69M | -$4.43M | -$5.98M | -$7.47M |
| EPS (basic) | -2.37 | -0.72 | -0.87 | -1.19 | -0.58 |
| EPS (diluted) | -2.37 | -0.72 | -0.87 | -1.19 | -0.58 |
| Weighted avg. shares (diluted) | 494.60M | 494.49M | 494.49M | 494.49M | 12.81M |
| Balance sheet | |||||
| Cash & equivalents | $14.19M | $2.42M | $2.96M | $1.56M | $6.42M |
| Short-term investments | — | $2.48M | $5.00M | $10.00M | $10.00M |
| Current assets | $14.22M | $4.90M | $8.11M | $11.62M | $16.44M |
| PP&E, net | $135,112 | $215,434 | $141,734 | $440,829 | $712,594 |
| Total assets | $14.73M | $5.76M | $8.44M | $12.62M | $18.02M |
| Current liabilities | $1.32M | $663,673 | $193,578 | $606,914 | $577,764 |
| Total liabilities | $1.38M | $895,308 | $219,512 | $632,320 | $938,032 |
| Shareholders' equity | $13.35M | $4.86M | $8.22M | $12.03M | $17.07M |
| Shares outstanding | 495.88M | 494.49M | 494.49M | 13.01M | 13.01M |
| Cash flow statement | |||||
| Operating cash flow | -$7.70M | -$3.11M | -$4.00M | -$4.96M | -$5.27M |
| Capital expenditure | — | $152,689 | $5,376 | $27,392 | $780,876 |
| Free cash flow | — | -$3.27M | -$4.01M | -$4.99M | -$6.05M |
| Investing cash flow | $2.50M | $2.69M | $5.24M | $58,978 | -$10.78M |
| Financing cash flow | $16.95M | — | $102,282 | $134,913 | $22.41M |
| Depreciation & amortization | $80,908 | $77,692 | $305,780 | $293,135 | $150,147 |
| Stock-based compensation | $3.23M | $244,808 | $449,311 | $922,623 | $2.76M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.